title: Craniopharyngioma in childhood.
abstract: In summary, much progress has been made in our understanding of childhood craniopharyngiomas. These histologically benign but "geographically malignant" tumors are challenging to treat and require experienced clinicians from multiple disciplines including neurosurgery, radiology, hematology/oncology, ophthalmology, endocrinology, and general pediatrics to address the multiple issues that arise with diagnosis, treatment, and long-term follow-up of affected children. The study and close observation of patients who have craniopharyngiomas may also be beneficial for our general understanding of pathophysiologic processes such as the observed "growth without growth hormone" phenomenon or the well-described and studied hypothalamic obesity phenotypes.
authors.affiliation: Division of Endocrinology, Diabetes, and Metabolism, Childrens Hospital Los Angeles, Keck School of Medicine, University of Southern California, 4650 Sunset Boulevard, MS #61, Los Angeles, CA 90027, USA. jmay@chla.usc.edu
authors.forename: Joshua A
authors.initials: JA
authors.lastname: May
authors.forename: Mark D
authors.initials: MD
authors.lastname: Krieger
authors.forename: Ira
authors.initials: I
authors.lastname: Bowen
authors.forename: Mitchell E
authors.initials: ME
authors.lastname: Geffner
mesh_terms: D002648:Child; D003131:Combined Modality Therapy; D003397:Craniopharyngioma / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D013006:Growth Hormone / Q000627:therapeutic use; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D009765:Obesity / Q000503:physiopathology; D010911:Pituitary Neoplasms / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D011879:Radiotherapy Dosage; D051153:Wnt Proteins / Q000235:genetics
chemical_list: D051153:Wnt Proteins; D013006:Growth Hormone